ADRO:NSD-Aduro Biotech, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.49

Change

-0.12 (-4.60)%

Market Cap

USD 0.21B

Volume

0.16M

Average Target Price

USD 3.75 (+50.60%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aduro Biotech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation clinical trial and Phase Ib dose escalation clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase II clinical trial in combination with pembrolizumab, an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck. It is also developing product candidates to prevent or control immune responses through the stimulator of interferon genes pathway. In addition, the company is developing BION-1301, a fully blocking humanized monoclonal anti-APRIL antibody that is in Phase I clinical trial for IgA nephropathy; and CD27, a co-stimulatory receptor, which is in preclinical studies expressed on different immune cells, such as T-lymphocytes and natural killer cells. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Eli Lilly and Company, and Merck Sharp and Dohme B.V.; and license agreements with Karagen Pharmaceuticals, Inc., UC Berkeley, and Memorial Sloan Kettering Cancer Center. The company was formerly known as Oncologic, Inc. and changed its name to Aduro Biotech, Inc. in June 2008. Aduro Biotech, Inc. was founded in 2000 and is headquartered in Berkeley, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+3.91 (+1.46%)

USD69.69B 32.32 25.77
REGN Regeneron Pharmaceuticals, Inc

-4.15 (-0.73%)

USD63.99B 21.32 16.47
SGEN Seattle Genetics, Inc

-0.96 (-0.54%)

USD30.73B N/A N/A
MRNA Moderna, Inc

-0.95 (-1.38%)

USD27.16B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

-2.44 (-2.09%)

USD25.55B 28.27 25.54
RPRX Royalty Pharma plc

+0.67 (+1.65%)

USD24.71B 33.37 9.15
GMAB Genmab A/S

+0.27 (+0.72%)

USD24.24B 25.60 2.90
BGNE BeiGene, Ltd

+7.49 (+2.94%)

USD23.25B N/A N/A
IMMU Immunomedics, Inc

-0.02 (-0.02%)

USD19.73B N/A N/A
INCY Incyte Corporation

+0.48 (+0.53%)

USD19.67B 47.64 35.20

ETFs Containing ADRO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 111.02% 87% B+ 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 111.02% 87% B+ 92% A-
Trailing 12 Months  
Capital Gain 99.20% 81% B- 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 99.20% 81% B- 90% A-
Trailing 5 Years  
Capital Gain -89.50% 22% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -89.50% 22% F 7% F
Average Annual (5 Year Horizon)  
Capital Gain -32.32% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -32.32% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 39.86% N/A N/A N/A N/A
Risk Adjusted Return -81.09% N/A N/A N/A N/A
Market Capitalization 0.21B 43% F 42% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.54 45% F 29% F
Price / Cash Flow Ratio -3.23 36% F 70% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -87.44% 37% F 15% F
Return on Invested Capital -87.33% 31% F 11% F
Return on Assets -13.90% 80% B- 24% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 5.11 44% F 32% F
Short Percent 5.00% 59% F 39% F
Beta 0.29 92% A- 88% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector